The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market share, while Asia-Pacific is the fastest-growing region at 10.89% CAGR.

The global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.

The report examines the trends shaping the orphan designated drugs market, including healthcare, technology, macroeconomic, and regulatory factors. It provides insights into leading players and future challengers across the value chain, as well as key drugs and markets.

The global intravenous solutions market is projected to grow at a CAGR of 8.0% from 2024 to 2031, driven by the increasing elderly population, rising rates of chronic diseases, and advancements in medical technology.

The global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.

The global RFID Kanban systems market is expected to reach $9.53 billion by 2030, driven by increasing demand for real-time asset and inventory tracking. North America, particularly the U.S. hospital inventory management market, is expected to see high growth potential for RFID Kanban solutions.

BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo® during the next seven years, following recent Food and Drug Administration (FDA) approval to treat primary immunodeficiencies (PID).

BARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group Corporation (Haier Group) and forged a strategic alliance with Haier Group. The deal has received all necessary regulatory approvals and compliance confirmation from the Shenzhen Stock Exchange.

BARCELONA, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration (FDA) for Yimmugo®, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary immunodeficiencies (PID).

BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially celebrated the 50th anniversary of its flagship site in Clayton, N.C., whose production of these essential therapeutics during its existence has saved the lives of millions of patients.

U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday. Shares of CarMax, Inc. (NYSE: KMX) fell sharply in today’s pre-market trading after the company reported lower-than-expected fourth-quarter earnings. CarMax posted quarterly earnings of 32 cents per share, missing market estimates of 49 cents per share. The company’s quarterly sales came in at $5.63 billion versus expectations of $5.79 billion, according to data from Benzinga Pro. CarMax shares dipped 9.1% to $72.06 in pre-market trading. Here are some big stocks recording losses in today’s pre-market ...

Smart Beta ETF report for FBT